$MIRA

MIRA PHARMACEUTICALS, INC. (MIRA) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 MIRA Pharmaceuticals Reports Significant Weight and Fat Reduction With Oral SKNY-1 in Obese Mice, Showing Favorable Lean-Mass and Weight-Regain Outcomes Compared With Semaglutide SKNY-1’s Weight Reduction Without Significant Changes in Food Consumption Suggests a Pot

MIRA Pharmaceuticals reported that its drug MIRA-55 showed comparable pain relief to celecoxib in a 21-day preclinical study, reducing pain and inflammation without adverse effects. The company plans to submit an IND application in Q1 2027, pending further preclinical and regulatory work.

MIRA PHARMACEUTICALS, INC. (MIRA) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 MIRA Pharmaceuticals Reports MIRA-55 Demonstrated Significant Pain Relief Comparable to Celebrex in Chronic Inflammatory Pain Study Positive IND-Enabling Proof-of-Concept Study Demonstrates Sustained Efficacy Without Observed Tolerance, Reduced Inflammation-Associate

MIRA PHARMACEUTICALS, INC. (MIRA) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review Protocol Submitted for IRB Review at a Leading Cancer Research Institution, Advancing the Study Toward Site Initiation MIAMI, Sept. 17, 2026

MIRA PHARMACEUTICALS, INC. (MIRA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of a Matter to a Vote of Security Holders. On September 11, 2026, MIRA Pharmaceuticals, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The record date for stockholders entitled to notice of the Annual Meeting was Ju

MIRA Pharmaceuticals (NASDAQ:MIRA) reported preclinical formulation results for its oral candidate MIRA-55 for chronic inflammatory pain. The company says a selected lead formulation showed favorable oral bioavailability with sustained exposure and reproducible distribution to brain and liver after oral dosing, supported by an IV reference arm. MIRA plans further preclinical work linking tissue exposure to pharmacodynamic activity.

MIRA Pharmaceuticals (NASDAQ:MIRA) shares were flat at the open. The company said new preclinical pharmacology data for its cannabinoid analog Mira-55 in chronic inflammatory pain showed a THC-like receptor profile but different effects, including an anxiolytic effect not seen with THC. MIRA also referenced March 2026 animal data versus rimonabant.

MIRA PHARMACEUTICALS, INC. (MIRA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 Consulting Agreement This Consulting Agreement (this “Agreement”) is entered into as of June 6, 2026 (“Effective Date”) by and between MIRA Pharmaceuticals, Inc. (“Company”), and Andriy Mushak (“Consultant”). Company and Consultant may be

MIRA Pharmaceuticals Inc ( NASDAQ:MIRA ) shares are trading significantly higher on Thursday following the announcement of new preclinical data for its lead candidate Mira-55.

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.34% to 46,412.27 while the NASDAQ climbed 0.73% to 22,834.55. The S&P 500 also rose, gaining, 0.41% to 6,698.54.